Peregrine Capital Management LLC Esperion Therapeutics, Inc. Transaction History

Peregrine Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Oct 18, 2018	SELL	$40.74 - $51.41 $6.89 Million - $8.7 Million	-169,239 Closed	0 $0
Q2 2018 Jul 12, 2018	SELL	$36.2 - $76.4 $370,108 - $781,113	-10,224 Reduced 5.7%	169,239 $0
Q1 2018 Apr 16, 2018	SELL	$65.94 - $80.76 $5.05 Million - $6.19 Million	-76,629 Reduced 29.92%	179,463 $0
Q4 2017 Jan 24, 2018	SELL	$43.47 - $67.43 $1.48 Million - $2.29 Million	-33,935 Reduced 11.7%	256,092 $0
Q3 2017 Oct 25, 2017	BUY	$43.8 - $52.77 $12.7 Million - $15.3 Million	290,027	290,027 $0

207

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $168M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Peregrine Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Peregrine Capital Management LLC with notifications on news.